These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 37395092

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. The newly synthesized 2-arylnaphthyridin-4-one, CSC-3436, induces apoptosis of non-small cell lung cancer cells by inhibiting tubulin dynamics and activating CDK1.
    Chang LC, Yu YL, Liu CY, Cheng YY, Chou RH, Hsieh MT, Lin HY, Hung HY, Huang LJ, Wu YC, Kuo SC.
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1303-15. PubMed ID: 25947085
    [Abstract] [Full Text] [Related]

  • 25. A novel small-molecule PI3K/Akt signaling inhibitor, W934, exhibits potent antitumor efficacy in A549 non-small-cell lung cancer.
    Wang J, Wang HY, Shen Y, Liang D, Wang HY, Zhang SQ, Cao YX, Cao L.
    Anticancer Drugs; 2019 Oct; 30(9):900-908. PubMed ID: 30913062
    [Abstract] [Full Text] [Related]

  • 26. Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Zhu X, Jiang H, Li J, Xu J, Fei Z.
    Med Sci Monit; 2016 Apr 29; 22():1435-41. PubMed ID: 27125283
    [Abstract] [Full Text] [Related]

  • 27. The anticancer effects of Cucurbitacin I inhibited cell growth of human non‑small cell lung cancer through PI3K/AKT/p70S6K pathway.
    Zhu X, Huang H, Zhang J, Liu H, Ao R, Xiao M, Wu Y.
    Mol Med Rep; 2018 Feb 29; 17(2):2750-2756. PubMed ID: 29207097
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells.
    Lee H, Kim SJ, Jung KH, Son MK, Yan HH, Hong S, Hong SS.
    Oncol Rep; 2013 Aug 29; 30(2):863-9. PubMed ID: 23708425
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Dual roles of miR-374a by modulated c-Jun respectively targets CCND1-inducing PI3K/AKT signal and PTEN-suppressing Wnt/β-catenin signaling in non-small-cell lung cancer.
    Zhao M, Xu P, Liu Z, Zhen Y, Chen Y, Liu Y, Fu Q, Deng X, Liang Z, Li Y, Lin X, Fang W.
    Cell Death Dis; 2018 Jan 23; 9(2):78. PubMed ID: 29362431
    [Abstract] [Full Text] [Related]

  • 34. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A, Li H, Li R, Lu L, Wu X.
    Oncol Rep; 2018 Oct 23; 40(4):2353-2362. PubMed ID: 30066933
    [Abstract] [Full Text] [Related]

  • 35. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
    Yang J, Qin G, Luo M, Chen J, Zhang Q, Li L, Pan L, Qin S.
    Cell Death Dis; 2015 Jul 23; 6(7):e1829. PubMed ID: 26203858
    [Abstract] [Full Text] [Related]

  • 36. The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling.
    Wang J, Ma S, Chen X, Zhang S, Wang Z, Mei Q.
    Invest New Drugs; 2019 Oct 23; 37(5):828-836. PubMed ID: 30456603
    [Abstract] [Full Text] [Related]

  • 37. 5-(3,4,5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) targets tubulin and DNA to induce anticancer activity and overcome multidrug resistance in colorectal cancer cells.
    Bai Z, Liu X, Guan Q, Ding N, Wei Q, Tong B, Zhao M, Zhang W, Ma L.
    Chem Biol Interact; 2020 Jan 05; 315():108886. PubMed ID: 31682804
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
    Bao R, Lai CJ, Wang DG, Qu H, Yin L, Zifcak B, Tao X, Wang J, Atoyan R, Samson M, Forrester J, Xu GX, DellaRocca S, Borek M, Zhai HX, Cai X, Qian C.
    Mol Cancer Ther; 2009 Dec 05; 8(12):3296-306. PubMed ID: 19952121
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.